Martin Shkreli is one of the few personalities of modern American business history who have produced a lot of discussion. A financially gifted entrepreneur with an incredible gift of finance and biotechnology, his career path led him through Wall Street internships at age seventeen to the head of the drug business sector, and eventually into one of the most pronounced, well-known legal cases in the recent history of the corporation.
Humble Brooklyn Beginnings
Shkreli was brought up in Sheepshead Bay, Brooklyn, with Albanian and Croatian immigrant parents who were janitors. He had an early interest in science and finance that secured him an internship on Wall Street.
Wall Street at Seventeen
At the age of seventeen, Shkreli got an internship in the hedge fund Cramer Berkowitz and Company, which exposed him to the world of financial markets at a tender age. Along with the establishment of his own projects, he graduated from Baruch College in 2004 and got his degree in business administration.
Constructing a Pharmaceutical Empire
Before creating Retrophin and later Turing Pharmaceuticals, Shkreli cofounded MSMB Capital Management, a reputation for being unconventional but an enthusiast with financial ambitions in the hedge fund investment sector and the pharmaceutical sector at the same time, weaving its pattern across the two sectors simultaneously over his career.
The Daraprim Decision
In 2015, Turing Pharmaceuticals bought Daraprim, an antiparasitic drug taken by immunocompromised patients, and increased its price overnight by thirteen dollars fifty cents to seven hundred and fifty dollars per pill.
A 5,500 Percent Price Increase
The more than five hundred percent price hike was criticized by more than two hundred medical organizations, nonprofit groups, lawmakers, and all the same and immediate major presidential candidates at the same time.
Congressional Hearing
Shkreli was subpoenaed to testify before the House Committee on Oversight and Government Reform on the matter of the Daraprim price increase. After receiving legal advice, he used his Fifth Amendment right and refused to answer the questions of the committee the whole time.
Conviction Fraud Securities
A federal jury convicted Shkreli in August 2017 of two counts of securities fraud and one count of conspiracy in his management of hedge funds MSMB Capital Management and Retrophin, respectively.
Seven-Year Sentence
Shkreli was found guilty of 7 years in federal jail on March 9 2018. The judge has observed that there was actual remorse when sentencing but he also realized that the misconduct committed was serious because it was done across several business organizations over his career.
Life After Prison
Reappearing in May 2022, after being banned permanently in the pharmaceutical industry, Shkreli came back to the life of social media to conduct financial analysis and comment on stocks and to survive the considerable legal and professional repercussions of his earlier actions.
